Abstract
The epidermal growth factor receptor (EGFR) has become an important molecular target in cancer therapy. Various small molecules and therapeutic antibodies targeting EGFR family members have been developed during recent years and are established in clinical oncology. However, increasing clinical application of EGFR tyrosine kinase inhibitors has resulted in the development of resistance to EGFR-targeting drugs due to the selection of EGFR-mutated variants. This phenomenon forced the search for novel EGFR inhibitors with activity towards EGFR-mutant tumors. This review describes recent achievements in natural products derived from medicinal plants as novel EGFR inhibitors.
Keywords: Cancer, drug resistance, epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitor, medicinal plant, natural product, head and neck squamous cell cancer, HNSCC, renal cancer, ovarian cancer, vinblastine, vincristine, paclitaxel, camptothecin, Cephalotaxus hainanensis, cephalotaxine, CET, ester homoharringtonine, Artemisia annua, Magnolia officinalis, small cell carcinoma, SCC, non-small cell carcinoma, small cell lung carcinoma, SCLC, cell lung carcinoma, NSCLC, Oral squamous cell carcinoma, OSCC, Magnoliae Cortex, CPT, Lithospermum erythrorhizon, Rabdosia rubescens, Lithospermum radix
Combinatorial Chemistry & High Throughput Screening
Title: Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor
Volume: 13 Issue: 10
Author(s): Serkan Sertel, Peter K. Plinkert and Thomas Efferth
Affiliation:
Keywords: Cancer, drug resistance, epidermal growth factor receptor (EGFR), EGFR tyrosine kinase inhibitor, medicinal plant, natural product, head and neck squamous cell cancer, HNSCC, renal cancer, ovarian cancer, vinblastine, vincristine, paclitaxel, camptothecin, Cephalotaxus hainanensis, cephalotaxine, CET, ester homoharringtonine, Artemisia annua, Magnolia officinalis, small cell carcinoma, SCC, non-small cell carcinoma, small cell lung carcinoma, SCLC, cell lung carcinoma, NSCLC, Oral squamous cell carcinoma, OSCC, Magnoliae Cortex, CPT, Lithospermum erythrorhizon, Rabdosia rubescens, Lithospermum radix
Abstract: The epidermal growth factor receptor (EGFR) has become an important molecular target in cancer therapy. Various small molecules and therapeutic antibodies targeting EGFR family members have been developed during recent years and are established in clinical oncology. However, increasing clinical application of EGFR tyrosine kinase inhibitors has resulted in the development of resistance to EGFR-targeting drugs due to the selection of EGFR-mutated variants. This phenomenon forced the search for novel EGFR inhibitors with activity towards EGFR-mutant tumors. This review describes recent achievements in natural products derived from medicinal plants as novel EGFR inhibitors.
Export Options
About this article
Cite this article as:
Sertel Serkan, K. Plinkert Peter and Efferth Thomas, Natural Products Derived from Traditional Chinese Medicine as Novel Inhibitors of the Epidermal Growth Factor Receptor, Combinatorial Chemistry & High Throughput Screening 2010; 13 (10) . https://dx.doi.org/10.2174/138620710793360266
DOI https://dx.doi.org/10.2174/138620710793360266 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Metallic Colloid Nanotechnology, Applications in Diagnosis and Therapeutics
Current Pharmaceutical Design Detection of Unilateral Hearing Loss by Stationary Wavelet Entropy
CNS & Neurological Disorders - Drug Targets Epidermal Growth Factor Receptors: A Functional Perspective
Current Radiopharmaceuticals MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Role of Glucocorticoids in Breast Cancer
Current Pharmaceutical Design Clinical Applications of the Urokinase Receptor (uPAR) for Cancer Patients
Current Pharmaceutical Design Palladacycles as Antimicrobial Agents
Current Medicinal Chemistry RGD Peptide–mediated Molecular Imaging for Targeting Integrin Alpha(v) Beta(3) in Tumors: A Review
Current Medical Imaging Metabotropic Glutamate Receptors: A Review on Prospectives and Therapeutic Aspects
Mini-Reviews in Medicinal Chemistry Significance of High Levels of Endogenous Melatonin in Mammalian Cerebrospinal Fluid and in the Central Nervous System
Current Neuropharmacology Deregulation of the Akt Pathway in Human Cancer
Current Cancer Drug Targets Roles of p75NTR in Maintaining Brain Hemostasis and the Implications for p75NTR-targeted Therapies
Current Alzheimer Research Opportunities and Challenges for Host-Directed Therapies in Tuberculosis
Current Pharmaceutical Design Evaluation of Natural and Synthetic Compounds from East Asiatic Folk Medicinal Plants on the Mediation of Cancer
Anti-Cancer Agents in Medicinal Chemistry Hexokinase II: The Integration of Energy Metabolism and Control of Apoptosis
Current Medicinal Chemistry Existing Drug Repurposing for Glioblastoma to Discover Candidate Drugs as a New a Approach
Letters in Drug Design & Discovery Recent Development of Anticancer Therapeutics Targeting Akt
Recent Patents on Anti-Cancer Drug Discovery Protein-Modified Magnetic Nanoparticles for Biomedical Applications
Current Organic Chemistry MicroRNA Mediated Network and DNA Methylation in Colorectal Cancer
Protein & Peptide Letters Possible Targets of Herbals for Type 3 Diabetes: A Review
Current Traditional Medicine